{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T12:52:33Z","timestamp":1762606353123},"reference-count":32,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2013,12,16]],"date-time":"2013-12-16T00:00:00Z","timestamp":1387152000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0082325","type":"journal-article","created":{"date-parts":[[2013,12,16]],"date-time":"2013-12-16T16:34:18Z","timestamp":1387211658000},"page":"e82325","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":24,"title":["Factors Associated With the Time to Next Attack in Neuromyelitis Optica: Accelerated Failure Time Models With Random Effects"],"prefix":"10.1371","volume":"8","author":[{"given":"Sung-Min","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junwoo","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sun Hee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su-Yeon","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jee Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung-Joon","family":"Sung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung Seok","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwang-Woo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2013,12,16]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3988\/jcn.2011.7.3.115","article-title":"New insights into neuromyelitis optica","volume":"7","author":"W Kim","year":"2011","journal-title":"J Clin Neurol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","article-title":"2006) Revised diagnostic criteria for neuromyelitis optica","volume":"66","author":"DM Wingerchuk","year":"2006","journal-title":"Neurology"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1212\/01.wnl.0000254502.87233.9a","article-title":"A secondary progressive clinical course is uncommon in neuromyelitis optica","volume":"68","author":"DM Wingerchuk","year":"2007","journal-title":"Neurology"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1212\/WNL.0b013e31822a2780","article-title":"Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica","volume":"77","author":"C Costanzi","year":"2011","journal-title":"Neurology"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/archneurol.2009.175","article-title":"Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients","volume":"66","author":"A Jacob","year":"2009","journal-title":"Arch Neurol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1001\/archneurol.2011.154","article-title":"Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years","volume":"68","author":"SH Kim","year":"2011","journal-title":"Arch Neurol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1001\/archneurol.2010.322","article-title":"Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica","volume":"68","author":"SH Kim","year":"2011","journal-title":"Arch Neurol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/jech.2004.030759","article-title":"Applied analysis of recurrent events: a practical overview","volume":"59","author":"JW Twisk","year":"2005","journal-title":"J Epidemiol Community Health"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1212\/WNL.0b013e318296e917","article-title":"Aquaporin-4 antibody-negative neuromyelitis optica: distinct assay sensitivity-dependent entity","volume":"80","author":"R Marignier","year":"2013","journal-title":"Neurology"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1177\/1352458512472748","article-title":"Utility of aquaporin-4 antibody assay in patients with neuromyelitis optica spectrum disorders","volume":"19","author":"SM Kim","year":"2013","journal-title":"Mult Scler"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1001\/archneur.65.7.913","article-title":"Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis","volume":"65","author":"P Waters","year":"2008","journal-title":"Arch Neurol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/ana.1032","article-title":"Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis","volume":"50","author":"WI McDonald","year":"2001","journal-title":"Ann Neurol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1177\/1352458512457841","article-title":"Time to first relapse as an endpoint in multiple sclerosis clinical trials","volume":"19","author":"MP Sormani","year":"2013","journal-title":"Mult Scler"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/ana.410130302","article-title":"New diagnostic criteria for multiple sclerosis: guidelines for research protocols","volume":"13","author":"CM Poser","year":"1983","journal-title":"Ann Neurol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1093\/brain\/aws109","article-title":"Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan","volume":"135","author":"J Kitley","year":"2012","journal-title":"Brain"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1002\/sim.4780071105","article-title":"Heterogeneity in survival analysis","volume":"7","author":"OO Aalen","year":"1988","journal-title":"Stat Med"},{"key":"ref17","article-title":"Survival analysis using the SAS system : a practical guide","author":"PD Allison","year":"1995"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3414\/ME0478","article-title":"Modeling repeated time-to-event health conditions with discontinuous risk intervals. An example of a longitudinal study of functional disability among older persons","volume":"47","author":"Z Guo","year":"2008","journal-title":"Methods Inf Med"},{"key":"ref19","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4612-1304-8","article-title":"Analysis of multivariate survival data","author":"P Hougaard","year":"2000"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1001\/jama.1993.03510100083038","article-title":"The clinical evaluation of new drugs for sepsis. A prospective study design based on survival analysis","volume":"270","author":"WA Knaus","year":"1993","journal-title":"JAMA"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/BF02294361","article-title":"Model selection and Akaike&apos;s information criterion (AIC): The general theory and its analytical extensions","volume":"52","author":"H Bozdogan","year":"1987","journal-title":"Psychometrika"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1001\/archneurol.2011.170","article-title":"Use of mitoxantrone in neuromyelitis optica","volume":"68","author":"JL Kitley","year":"2011","journal-title":"Arch Neurol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/archneurol.2009.175","article-title":"Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients","volume":"66","author":"A Jacob","year":"2009","journal-title":"Arch Neurol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1212\/01.WNL.0000159399.81861.D5","article-title":"An open label study of the effects of rituximab in neuromyelitis optica","volume":"64","author":"BA Cree","year":"2005","journal-title":"Neurology"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1007\/s00415-011-6086-x","article-title":"Cerebrospinal fluid\/serum gradient of IgG is associated with disability at acute attacks of neuromyelitis optica","volume":"258","author":"SM Kim","year":"2011","journal-title":"J Neurol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S0140-6736(95)92710-7","article-title":"Autologous bone-marrow transplants compared with chemotherapy for children with acute lymphoblastic leukaemia in a second remission: a matched-pair analysis. The Berlin-Frankfurt-Munster Study Group","volume":"346","author":"A Borgmann","year":"1995","journal-title":"Lancet"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/(SICI)1097-0258(19970130)16:2<215::AID-SIM481>3.0.CO;2-J","article-title":"The role of frailty models and accelerated failure time models in describing heterogeneity due to omitted covariates","volume":"16","author":"N Keiding","year":"1997","journal-title":"Stat Med"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1001\/archneurol.2010.203","article-title":"Neuromyelitis optica treatment: analysis of 36 patients","volume":"67","author":"DB Bichuetti","year":"2010","journal-title":"Arch Neurol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1136\/jnnp.2007.143529","article-title":"Relapsing neuromyelitis optica: long term history and clinical predictors of death","volume":"80","author":"P Cabre","year":"2009","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","article-title":"The clinical course of neuromyelitis optica (Devic&apos;s syndrome)","volume":"53","author":"DM Wingerchuk","year":"1999","journal-title":"Neurology"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1212\/01.WNL.0000049912.02954.2C","article-title":"Neuromyelitis optica: clinical predictors of a relapsing course and survival","volume":"60","author":"DM Wingerchuk","year":"2003","journal-title":"Neurology"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1177\/1352458512457841","article-title":"Time to first relapse as an endpoint in multiple sclerosis clinical trials","volume":"19","author":"MP Sormani","year":"2013","journal-title":"Mult Scler"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0082325","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,4]],"date-time":"2019-08-04T20:13:34Z","timestamp":1564949614000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0082325"}},"subtitle":[],"editor":[{"given":"Pablo","family":"Villoslada","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2013,12,16]]},"references-count":32,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2013,12,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0082325","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,16]]}}}